Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318791 | 0.76 | CYP3A4 (0.44) | AKT1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL10764490 | 0.74 | CES1 (0.46) | ALDH1A1HPGDLMNAKDM4ECYP3A4 | |
| SCHEMBL28240816 | 0.73 | AKT1 (0.48) | AKT1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL6072498 | 0.73 | CES2 (0.48) | ALDH1A1LMNAKDM4ECES1MEN1 | |
| SCHEMBL1387178 | 0.72 | CES1 (0.48) | ALDH1A1HPGDLMNAKDM4ECYP3A4 | |
| SCHEMBL9743657 | 0.72 | GSK3B (0.52) | ALDH1A1HPGDLMNAKDM4ECYP3A4 | |
| SCHEMBL5655048 | 0.72 | ALDH1A1 (0.43) | AKT1ALDH1A1HPGDLMNAKDM4E | |
| SCHEMBL1649521 | 0.72 | TGM2 (0.52) | SMN1; SMN2TSHRNAPRT | |
| SCHEMBL5448548 | 0.72 | THRB (0.40) | ALDH1A1HPGDKDM4ECYP3A4MEN1 | |
| SCHEMBL23532647 | 0.71 | KDM4E (0.42) | AKT1ALDH1A1HPGDLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | claimed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | claimed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | claimed |
| JP-4460292-B2 | — | — | 2010-05-12 | — | — | JP | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | claimed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| EP-0567968-A1 | Cyclic imino derivatives, medicaments containing these compounds and processes for the production thereof | Dr. Karl Thomae GmbH (DE) | 1993-11-03 | — | — | EP | claimed |
| EP-0546387-A1 | Substituted oximetheramides | BAYER AG (DE) | 1993-06-16 | — | — | EP | claimed |
| EP-0102318-B1 | PREPARATION OF BETA-AMINO-ALPHA,BETA-UNSATURATED CARBOXYLIC-ACID ESTERS | CIBA-GEIGY AG (CH) | 1987-01-14 | — | — | EP | claimed |
| EP-0055562-B1 | CEPHALOSPORIN DERIVATIVES | ICI PHARMA (FR) | 1986-02-12 | — | — | EP | claimed |
| US-4496560-A | ACTIVE AGAINST GRAMPOSITIVE BACTERIA | RHONE-POULENC SANTE (FR) | 1985-01-29 | — | — | US | claimed |
| US-4492692-A | BACTERICIDE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-08 | — | — | US | claimed |
| EP-0055099-B1 | PENICILLIN DERIVATIVES | ICI PHARMA (FR) | 1984-10-24 | — | — | EP | claimed |
| EP-0075434-A2 | Cephalosporins, their preparation and their pharmaceutical compositions | ICI PHARMA (FR) | 1983-03-30 | — | — | EP | claimed |
| EP-0071370-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | ICI PHARMA (FR) | 1983-02-09 | — | — | EP | claimed |
| EP-0055099-A1 | Penicillin derivatives | ICI PHARMA (FR) | 1982-06-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | AKT1 2736/4885ALDH1A1 252/4885HPGD 529/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | AKT1 2736/4885ALDH1A1 252/4885HPGD 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.